Newsletter | June 9, 2022

06.09.22 -- Manufacturing Strategies For Advanced Therapeutics

Unprecedented Growth — And Challenges — In Gene Therapy

The gene therapy clinical pipeline is in a high-growth phase, with an influx of venture capital funding. There are also challenges: scalability, dosing, and the price of the final treatment.

Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness

A rationale-based methodology to address T-cell manufacturing challenges, based on the intended final manufacturing process, proposes a robust, scalable, cost-effective, and sustainable allogeneic platform.

Manufacturing Strategies To Industrialize Autologous Cell Therapies

While the first autologous cell therapy commercial products have shown tremendous clinical success, scaling out these therapies while considering individual patient processes is a new challenge.

Integrated Solutions For Advanced Therapeutics

Our development expertise across all gene therapy modalities (AAV, lentivirus, oncolytic virus, etc.) and proven clinical through commercial scale-up capabilities will provide full life cycle support of your life-saving therapeutic.

Request Information